Goldman Sachs Group Inc Madrigal Pharmaceuticals, Inc. Call Options Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 13, 2024	BUY	$193.33 - $291.99 $231,996 - $350,388	1,200 Added 12.63%	10,700 $3 Million
Q4 2023 Feb 13, 2024	SELL	$120.4 - $237.13 $2.93 Million - $5.76 Million	-24,300 Reduced 71.89%	9,500 $2.2 Million
Q3 2023 May 14, 2024	BUY	$146.04 - $225.78 $3.55 Million - $5.49 Million	24,300 Added 255.79%	33,800 $4.94 Million
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $3.48 Million - $5.37 Million	23,800 Added 238.0%	33,800 $4.94 Million
Q2 2023 May 14, 2024	BUY	$203.88 - $312.0 $101,940 - $156,000	500 Added 5.26%	10,000 $2.31 Million
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $2.04 Million - $3.12 Million	10,000 New	10,000 $2.31 Million

297

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.34B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.